Pediatric Knee Cartilage Repair Moves Into Phase 3 Testing
A phase 3 study is testing whether MACI can offer better repair than microfracture for adolescents with symptomatic chondral or osteochondral defects of the knee. The PEAK trial is enrolling patients aged 10 to 17 years and places the comparison squarely in a population where durable cartilage restoration can shape years of mobility, sports participation, and pain control.
The study is open-label, randomized, multicenter, and designed to follow participants for 2 years after treatment. Thirty participants are assigned to MACI and 15 to microfracture, with the trial using a 2:1 allocation scheme across an estimated total enrollment of 45 patients. The treatment question is straightforward, but the biology is not: microfracture depends on marrow stimulation and fibrocartilaginous repair, while MACI uses a patient’s own cultured chondrocytes to rebuild articular cartilage in a more tissue-specific way.
Why the Trial Focuses on a Narrow Adolescent Population
The study population is deliberately restricted to a narrow age range. Adolescents with open growth potential, active sports exposure, and focal cartilage defects represent a clinical group in whom failed repair can echo through the rest of skeletal maturation. The protocol requires symptomatic lesions on the femoral condyles and/or trochlea, with at least one defect measuring 1.5 cm2 or larger on the patella, femoral condyles, or trochlea.
Eligibility also includes International Cartilage Repair Society Grade III or IV chondral defects or unsalvageable osteochondral defects. For osteochondritis dissecans, the protocol allows lesions with a bone depth of 6 mm or less, provided no bone graft is required. Salvageable OCD lesions must have failed conservative care and reparative treatment, and the adolescent must still have pain tied to the lesion. Trauma-related or idiopathic defects are also eligible, even without a prior treatment history.
This is an important distinction at the bedside. The trial is not studying diffuse cartilage degeneration or generalized knee pain. It is targeting focal structural pathology, where a mechanical defect and biologic failure intersect, and where surgical restoration may alter the trajectory of function more than symptom management alone.
How Randomization Happens Inside the Operating Room
The protocol is built around a screening arthroscopy before definitive assignment. After initial screening criteria are met, every participant undergoes arthroscopy to confirm eligibility and measure cartilage lesion size before any repair procedure is performed. Cartilage biopsy is collected during that same evaluation, and randomization occurs at the time of screening arthroscopy.
Participants assigned to microfracture undergo that procedure immediately during the screening arthroscopy. Those assigned to MACI return within 12 weeks for chondrocyte implantation by arthrotomy. The biopsy process is central to both pathways: tissue from participants randomized to MACI is used to prepare the implant, while tissue from those randomized to microfracture is cryopreserved.
The treatment sequence reflects a practical surgical reality. MACI requires a staged approach because the patient’s own chondrocytes must be isolated and expanded before implantation. Microfracture is completed in one setting, relying on the body’s own marrow-derived repair response. The contrast between those strategies is one reason the trial matters for pediatric orthopedics: it asks whether a more biologically tailored but staged cartilage procedure can outperform a simpler marrow stimulation technique in younger patients with focal disease.
Surgical Eligibility, Joint Stability, and the Cost of Failure
The entry criteria are strict in ways that matter clinically. The target knee must be stable, with no laxity of the anterior or posterior cruciate ligaments. Ligament repair or reconstruction is allowed before screening arthroscopy, but a stable mechanical environment is still required for enrollment. The meniscus must be intact or partially preserved, with at least 50% of the functional meniscus remaining.
Those restrictions are not administrative fine print. Cartilage repair fails more easily in a joint that remains mechanically abnormal. Instability, meniscal deficiency, and uncorrected alignment problems can continue to overload the repair site, undercutting any attempt at durable tissue restoration. In adolescents, that is especially consequential because the knee must absorb athletics, growth-related change, and repetitive load for years after surgery.
One particularly surgical nuance stands out. Participants with a potentially re-attachable osteochondral fragment identified on MRI may enter the study and proceed through baseline assessments before confirmatory arthroscopy. If reattachment succeeds, the participant is excluded as an intra-operative screen failure. If reattachment fails and no other exclusion criteria apply, the participant can remain in the trial, receive the MACI biopsy, and continue to randomization and treatment. The protocol therefore preserves flexibility for a subgroup in which fragment viability remains uncertain until direct visualization.
What the Two-Year Follow-Up Is Designed to Capture
Participants are followed for 104 weeks after study treatment. For a cartilage trial, that length of observation is clinically meaningful because early pain relief alone does not prove durable structural success. Repair tissue can behave differently under adolescent activity demands as months pass, rehabilitation progresses, and the repaired surface is repeatedly loaded.
Compliance with the postoperative rehabilitation schedule is monitored, which is critical because cartilage repair depends on controlled reintroduction of motion and load. A biologic implant or marrow-stimulated repair site cannot be judged apart from the mechanics of recovery. Rehab adherence can shape both symptom improvement and the integrity of the repair environment.
The trial is sponsored by Vericel Corporation, with study start listed as October 24, 2018, and estimated primary completion and study completion both set for February 2030. The study remains recruiting at multiple U.S. pediatric and orthopedic centers, including academic hospitals and children’s institutions across California, Louisiana, Maryland, Michigan, Ohio, Pennsylvania, Rhode Island, Texas, and Wisconsin.
Why This Comparison Matters in Pediatric Orthopedics
Cartilage defects in adolescents sit at a difficult intersection of symptoms, sport participation, and long-term joint preservation. Microfracture has the advantage of simplicity and single-stage delivery, but the repair tissue it generates is often mechanically and biologically different from native hyaline cartilage. MACI attempts a more specialized reconstruction by implanting autologous cultured chondrocytes into the defect, with the aim of supporting more cartilage-like repair.
The PEAK study is structured to test that tradeoff in a controlled fashion. By randomizing adolescents with focal lesions to one of these two surgical pathways, the trial is asking whether a cell-based strategy can justify its greater procedural complexity in a younger knee that still has decades of use ahead of it. The answer could influence how surgeons think about osteochondral lesions in patients who are too young to be treated like typical adult cartilage cases and too old to be assumed to outgrow the problem.
Enrollment is limited, the design is open-label, and the sample size is small. Those features mean the study may offer a focused view rather than a sweeping answer. Even so, the protocol makes the clinical question precise: in adolescents with symptomatic focal knee cartilage defects, does MACI deliver a more effective and safe path to repair than microfracture over two years of follow-up?